This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
- Vedco, Inc. of St. Joseph, Missouri selected as U.S. distributor -BELLEVILLE, ON,
Nov. 21, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has appointed an exclusive U.S. distributor for its
ImmunocidinTM canine oncology therapy:
St. Joseph, Missouri-based Vedco, Inc.
ImmunocidinTM was launched at the annual U.S. Veterinary Cancer Society conference in October of this year.
ImmunocidinTM is based on the Company's proprietary mycobacterial cell wall technology, the same platform from which its Phase III product for human bladder cancer (
ImmunocidinTM is indicated as an immunotherapy for the intratumoral treatment of mixed mammary tumor and mammary adenocarcinoma in dogs. The product has received regulatory approval in
Canada and the U.S. and is expected to be launched in
Canada in January, 2013.
Vedco will begin immediate distribution of
ImmunocidinTM to veterinarians via its group of member distributors which includes Butler Schein Animal Health, Merritt Veterinary Supply, Miller Veterinary Supply, MWI Veterinary Supply, Penn Veterinary Supply and Webster Veterinary Supply.
"We are pleased to have Vedco, Inc. as our U.S. distribution partner for this product," said Mr.
Andrew Grant, President, Bioniche Animal Health (global). "Vedco is known for its broad and respected distribution network, comprising more than 1,000 sales representatives throughout the U.S."
Unlike commonly used canine oncology therapies, such as chemotherapy,
Immunocidin TM does not require special handling and can be used by veterinarians in their own clinics, either alone or in combination with other therapies.
About Canine Cancer
Canine cancer is the leading disease-related cause of death in dogs, with approximately one in four dying of cancer.